ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer.
about
The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer.Low-dose glucocorticoids suppresses ovarian tumor growth and metastasis in an immunocompetent syngeneic mouse model.Development of a syngeneic mouse model of epithelial ovarian cancer.Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancerChronic delivery of a thrombospondin-1 mimetic decreases skeletal muscle capillarity in miceDoxorubicin synergizes with 34.5ENVE to enhance antitumor efficacy against metastatic ovarian cancer.Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: involvement of CB2Combined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy induces regression and significantly improves survival in a preclinical model of advanced stage epithelial ovarian cancer.Thrombospondin-1: multiple paths to inflammation.Thrombospondin peptide ABT-898 inhibits inflammation and angiogenesis in a colitis modelMolecular basis for the regulation of angiogenesis by thrombospondin-1 and -2.Identification of TAX2 peptide as a new unpredicted anti-cancer agent.Thrombospondin-1-Based Antiangiogenic Therapy.Thrombospondin-1 and pigment epithelium-derived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis.Ovarian tumour growth is characterized by mevalonate pathway gene signature in an orthotopic, syngeneic model of epithelial ovarian cancer.The thrombospondin-1 receptor CD36 is an important mediator of ovarian angiogenesis and folliculogenesis.Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitorsTherapies using anti-angiogenic peptide mimetics of thrombospondin-1.Antiangiogenic and anticancer molecules in cartilage.Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment.Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action.An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer.Thrombospondins function as regulators of angiogenesis.Extracellular matrix proteins and tumor angiogenesis.SCO-spondin oligopeptide inhibits angiogenesis in glioblastoma.Thrombospondin-I concentrations behavior in plasma of patients with ovarian cancer.Human expression patterns: qualitative and quantitative analysis of thrombospondin-1 under physiological and pathological conditions.Hydrophobic benzyl amines as supports for liquid-phase C-terminal amidated peptide synthesis: application to the preparation of ABT-510.
P2860
Q33727047-CB7C6E83-2C08-465A-881B-B7AE04C749A5Q33773081-F4846235-E207-4147-9236-9AA68C5C0BCEQ34282708-D3DA93D9-1804-4440-A879-0444815F3768Q34359284-4385E795-FE52-4288-8208-780E8B08C1D2Q34584625-EBDF1206-B28B-40E8-AD39-DC28C3A048AAQ34715771-284E99FA-3FEB-4730-ADB0-0A7CBA02D023Q34998169-00085A85-F95F-4F1F-AD33-2C7B6F92B26EQ35039333-4EE81EC8-B781-4484-91E7-3E5957E8941DQ35098885-3C3BDDF3-FADA-488D-9EB9-88D20670D79EQ35651465-D0390813-97F1-4E72-A7CB-F0593D7D0CF2Q35902676-19203231-F14C-4A08-A347-ACDBD1349E9FQ36228487-48D46D46-CCD0-452D-86E4-2720291DEE25Q36417463-B9887601-7D17-480C-AD28-ED9B42AF6B2BQ36586178-E27AB211-C781-4D5C-9A93-9C2D6ABD3A08Q37565136-F90CC5EF-B740-4CB2-BF4A-AFEC4296C50CQ37699686-2F0AE663-19C5-4215-84C2-543B09B4AD0DQ37840948-4E8FA4B5-79DA-4BB7-9F47-846562A833BBQ37963916-C0B0A7F7-1BD9-4A79-AB23-1995E14DA8AFQ38007565-81C5B11B-6C2C-41F0-9EDB-8647F76AADCFQ38787442-8B4A1734-9B17-49C2-A6CF-3674DFD1C11AQ38974266-0A348566-806F-4DAE-9DB4-8BFF09D8F6CAQ39325959-9D58FD20-ECEB-4864-92F6-E6BC9386BFC7Q42643939-2631F271-920E-42CF-9AF4-64B223FADD1DQ42699734-51D2FDFA-3889-4979-99E8-B0A5305140C7Q47106590-21F1D2FA-D941-4F0E-A374-51824B01C7F5Q47717341-752E4949-ADD8-4B6B-8650-5575D5792744Q50019794-D631D24B-4302-4F81-BE02-67CA2845810BQ51838553-B3084BE6-3BA3-491D-B7CF-4505DD18A687
P2860
ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
ABT-510 induces tumor cell apo ...... of epithelial ovarian cancer.
@ast
ABT-510 induces tumor cell apo ...... of epithelial ovarian cancer.
@en
type
label
ABT-510 induces tumor cell apo ...... of epithelial ovarian cancer.
@ast
ABT-510 induces tumor cell apo ...... of epithelial ovarian cancer.
@en
prefLabel
ABT-510 induces tumor cell apo ...... of epithelial ovarian cancer.
@ast
ABT-510 induces tumor cell apo ...... of epithelial ovarian cancer.
@en
P2093
P2860
P1476
ABT-510 induces tumor cell apo ...... of epithelial ovarian cancer.
@en
P2093
Jack Henkin
Jack Lawler
James Greenaway
Jim Petrik
Roger Moorehead
P2860
P356
10.1158/1535-7163.MCT-08-0864
P577
2009-01-01T00:00:00Z